Evaluating a new biomarker panel to predict liver transplant recipient mortality
Multi-Center Validation and Biologic Assessment of a Novel Pre-Transplant Biomarker Panel to Predict Liver Transplant Recipient Mortality
This study is testing a new way to predict which liver transplant patients might face more risks after their surgery, so doctors can better prioritize who gets a transplant first.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10882689 on NIH RePORTER |
What this research studies
This research aims to validate a novel biomarker panel called the Liver Immune Frailty Index (LIFI) that can predict the risk of mortality in patients receiving liver transplants. By measuring specific biomarkers before transplantation, the study seeks to identify patients who may have a higher risk of complications or death shortly after the procedure. The research will involve multiple centers to ensure a diverse patient population and robust results. If successful, this approach could help prioritize liver transplants for those most likely to benefit.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients listed for liver transplantation who may have underlying immune dysfunction or severe cirrhosis.
Not a fit: Patients who are not candidates for liver transplantation or those with stable immune function are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the selection process for liver transplant candidates, potentially reducing early post-transplant mortality.
How similar studies have performed: Previous studies have shown promise in using biomarker panels to predict transplant outcomes, suggesting that this approach may be effective.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Lunsford, Keri Elizabeth — Rutgers Biomedical and Health Sciences
- Study coordinator: Lunsford, Keri Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.